-DOCSTART- -X- O
Background -X- _ O
: -X- _ O
Pneumonia -X- _ O
caused -X- _ O
704,000 -X- _ O
deaths -X- _ O
in -X- _ O
children -X- _ O
younger -X- _ O
than -X- _ O
5 -X- _ O
years -X- _ O
in -X- _ O
2015. -X- _ O
Zinc -X- _ O
is -X- _ O
an -X- _ O
important -X- _ O
micronutrient -X- _ O
due -X- _ O
to -X- _ O
its -X- _ O
role -X- _ O
in -X- _ O
immune -X- _ O
function. -X- _ O
Since -X- _ O
2004 -X- _ O
, -X- _ O
WHO -X- _ O
recommends -X- _ O
zinc -X- _ B-Intervention
supplementation -X- _ I-Intervention
for -X- _ O
children -X- _ O
with -X- _ O
diarrhea -X- _ O
to -X- _ O
shorten -X- _ O
the -X- _ O
duration -X- _ O
and -X- _ O
decrease -X- _ O
severity. -X- _ O
Zinc -X- _ B-Intervention
supplementation -X- _ I-Intervention
for -X- _ O
children -X- _ B-Patient
with -X- _ I-Patient
pneumonia -X- _ I-Patient
is -X- _ O
controversial. -X- _ O
Methods -X- _ O
: -X- _ O
A -X- _ O
randomized -X- _ O
controlled -X- _ O
clinical -X- _ O
trial -X- _ O
was -X- _ O
conducted -X- _ O
, -X- _ O
and -X- _ O
103 -X- _ B-Patient
children -X- _ I-Patient
1 -X- _ I-Patient
month -X- _ I-Patient
to -X- _ I-Patient
5 -X- _ I-Patient
years -X- _ I-Patient
old -X- _ I-Patient
with -X- _ I-Patient
pneumonia -X- _ I-Patient
were -X- _ O
included. -X- _ O
Zinc -X- _ B-Patient
or -X- _ O
placebo -X- _ B-Comparison
was -X- _ O
given -X- _ O
during -X- _ O
hospitalization. -X- _ O
Clinical -X- _ O
symptoms -X- _ O
were -X- _ O
recorded -X- _ O
, -X- _ O
and -X- _ O
a -X- _ O
blood -X- _ O
draw -X- _ O
was -X- _ O
obtained -X- _ O
to -X- _ O
determine -X- _ O
serum -X- _ O
zinc -X- _ O
levels -X- _ O
, -X- _ O
lymphoproliferation -X- _ O
, -X- _ O
and -X- _ O
cytokines -X- _ O
at -X- _ O
hospitalization -X- _ O
and -X- _ O
at -X- _ O
discharge -X- _ O
of -X- _ O
the -X- _ O
patient -X- _ O
; -X- _ O
a -X- _ O
nasal -X- _ O
wash -X- _ O
was -X- _ O
obtained -X- _ O
to -X- _ O
detect -X- _ O
viral -X- _ O
or -X- _ O
bacterial -X- _ O
pathogens -X- _ O
by -X- _ O
multiplex -X- _ O
RT-PCR. -X- _ O
Results -X- _ O
: -X- _ O
Zinc -X- _ B-Outcome
supplementation -X- _ I-Outcome
improved -X- _ I-Outcome
in -X- _ I-Outcome
fewer -X- _ I-Outcome
hours -X- _ I-Outcome
the -X- _ I-Outcome
clinical -X- _ I-Outcome
status -X- _ I-Outcome
( -X- _ I-Outcome
76 -X- _ I-Outcome
± -X- _ I-Outcome
7 -X- _ I-Outcome
vs. -X- _ I-Outcome
105 -X- _ I-Outcome
± -X- _ I-Outcome
8 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.01 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
respiratory -X- _ I-Outcome
rate -X- _ I-Outcome
( -X- _ I-Outcome
37 -X- _ I-Outcome
± -X- _ I-Outcome
6 -X- _ I-Outcome
vs. -X- _ I-Outcome
57 -X- _ I-Outcome
± -X- _ I-Outcome
7 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.04 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
oxygen -X- _ I-Outcome
saturation -X- _ I-Outcome
( -X- _ I-Outcome
53 -X- _ I-Outcome
± -X- _ I-Outcome
7 -X- _ I-Outcome
vs. -X- _ I-Outcome
87 -X- _ I-Outcome
± -X- _ I-Outcome
9 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.007 -X- _ I-Outcome
) -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
placebo -X- _ I-Outcome
group. -X- _ I-Outcome
An -X- _ I-Outcome
increase -X- _ I-Outcome
in -X- _ I-Outcome
IFNγ -X- _ I-Outcome
and -X- _ I-Outcome
IL-2 -X- _ I-Outcome
after -X- _ I-Outcome
treatment -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
zinc -X- _ I-Outcome
group -X- _ I-Outcome
was -X- _ I-Outcome
observed. -X- _ I-Outcome
Conclusions -X- _ O
: -X- _ O
Zinc -X- _ B-Outcome
supplementation -X- _ I-Outcome
improved -X- _ I-Outcome
some -X- _ I-Outcome
clinical -X- _ I-Outcome
symptoms -X- _ I-Outcome
in -X- _ I-Outcome
children -X- _ I-Outcome
with -X- _ I-Outcome
pneumonia -X- _ I-Outcome
in -X- _ I-Outcome
fewer -X- _ I-Outcome
hours -X- _ I-Outcome
and -X- _ I-Outcome
induced -X- _ I-Outcome
a -X- _ I-Outcome
cellular -X- _ I-Outcome
immune -X- _ I-Outcome
response. -X- _ I-Outcome
Clinical -X- _ O
Trial -X- _ O
Registration -X- _ O
: -X- _ O
The -X- _ O
trial -X- _ O
was -X- _ O
retrospectively -X- _ O
registered -X- _ O
in -X- _ O
ClinicalTrials.gov -X- _ O
, -X- _ O
identifier -X- _ O
NCT03690583 -X- _ O
, -X- _ O
URL -X- _ O
https -X- _ O
: -X- _ O
/ -X- _ O
/ -X- _ O
clinicaltrials.gov -X- _ O
/ -X- _ O
ct2 -X- _ O
/ -X- _ O
show -X- _ O
/ -X- _ O
NCT03690583 -X- _ O
? -X- _ O
term=zinc+children -X- _ O
& -X- _ O
cond=Pneumonia -X- _ O
& -X- _ O
draw=2 -X- _ O
& -X- _ O
rank=1 -X- _ O
. -X- _ O

